Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Floege, J.
Right arrow Articles by Koch, K. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Floege, J.
Right arrow Articles by Koch, K. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2001) 16: 12-16
© 2001 European Renal Association-European Dialysis and Transplant Association


Scintigraphic methods to detect ß2-microglobulin associated amyloidosis (Aß2-microglobulin amyloidosis)

Jürgen Floege, Jürgen Schäffer1 and Karl Martin Koch1

Division of Nephrology, Department of Medicine, University of Aachen and 1 Division of Nephrology, Department of Medicine, University of Hannover, Germany

Abstract

ß2-Microglobulin-derived amyloidosis (Aß2m) represents a major cause or morbidity in patients with end-stage renal disease. Symptoms of Aß2m amyloid are mainly related to (peri-) articular amyloid deposition. Conventional non-invasive diagnostic techniques, i.e. clinical evaluation, joint ultrasonography or X-ray, computed tomography or magnetic resonance imaging findings, as well as conventional bone scans, suffer from relative non-specificity and/or low sensitivity. Two recent methods, namely scintigraphy with radiolabelled serum amyloid P component (SAP) or with the radiolabelled Aß2m-precursor protein, ß2-microglobulin (ß2m), yield more specific information. Using 123I-labelled SAP, Aß2m deposits have been visualized in several long-term haemodialysis (HD) patients. However, this scan did not show tracer accumulation in other frequently involved sites, such as hips or shoulders, but did frequently label the spleen, which is usually spared from Aß2m deposits. Scanning with 131I-labelled ß2m, in contrast, yielded tracer accumulations corresponding to the typical distribution pattern of Aß2m. Specificity of this method was shown by several methods, and the sensitivity was found to markedly exceed that of combined clinical and radiological investigations. Recently, both the radiation exposure and the optical resolution of this latter scan have been further refined by substituting 131I with 111In. In a final step we generated recombinant human ß2m (rhß2m). 111In-rhß2m again failed to show significant tracer accumulation over joint regions in patients on short-term HD without evidence of Aß2m amyloidosis. In contrast, local tracer accumulations similar to those observed with natural, 111In-labelled ß2m could be demonstrated in long-term HD patients with evidence of Aß2m amyloidosis. In conclusion, scintigraphy for Aß2m with 111In-labelled rhß2m provides a homogenous and safe recombinant protein source, and allows for the sensitive and specific non-invasive detection of Aß2m-amyloid deposits in dialysis patients.

Notes

Correspondence and offprint requests to: J. Floege, Medizinische Klinik II, University of Aachen, D-52057 Aachen, Germany.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.